ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma

NCT00144807 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

128

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large Cell Lymphoma

Interventions

DRUG: rituximab
DRUG: doxorubicin
DRUG: cyclophosphamide
PROCEDURE: autologous stem cell transplantation

Sponsor

Lymphoma Study Association